26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Precision medicine (PM) is changing the scope of allergy diagnosis and treatment. An in vitro IgE assay, a prototype PM method, was developed in the sixties and has garnered increasing interest because of the introduction of recombinant components in the test. More recently, microarrays of allergen components have significantly improved the ability to describe the IgE profile. Aim of this study was to evaluate the characteristics of the newly developed Allergy Explorer (ALEX), a macroarray containing both extracted “whole” allergens and molecular components. This method allows the acquisition of an IgE profile comprising 282 reagents (157 allergen extracts and 125 components), resulting in the widest screening of potential allergens available.

          Methods

          Sera from 43 patients with allergies were assayed with ALEX and then with ImmunoCAP ISAC. The results of the two tests were compared, and the consistency of the molecular results with the presence of IgE in the relevant extract was also evaluated.

          Results

          A good correlation between ISAC and ALEX was observed. The ALEX results for second-level tests (i.e., specific IgE to complete extracted allergens) were consistent with the results obtained for the relevant components.

          Discussion

          Despite differences in the methodology, the IgE profiles detected for molecular allergens by ALEX and ISAC were very similar. The differences were mainly related to the lower dynamic range of ALEX and to the use of a CCD inhibitor in the first incubation phase, which reduced the binding of IgE to CCD, as represented in the extracted allergens and components.

          Conclusion

          Based on our findings, ALEX is a novel tool for describing the IgE profile in a PM setting, where the IgE assay must be performed on many allergens and components. In particular, polysensitized patients and patients with pollen-food syndrome will have a real advantage due the combination of the second and third levels of allergy diagnostics in the same chip.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnostics

          Molecular-based allergy (MA) diagnostics is an approach used to map the allergen sensitization of a patient at a molecular level, using purified natural or recombinant allergenic molecules (allergen components) instead of allergen extracts. Since its introduction, MA diagnostics has increasingly entered routine care, with currently more than 130 allergenic molecules commercially available for in vitro specific IgE (sIgE) testing. MA diagnostics allows for an increased accuracy in allergy diagnosis and prognosis and plays an important role in three key aspects of allergy diagnosis: (1) resolving genuine versus cross-reactive sensitization in poly-sensitized patients, thereby improving the understanding of triggering allergens; (2) assessing, in selected cases, the risk of severe, systemic versus mild, local reactions in food allergy, thereby reducing unnecessary anxiety for the patient and the need for food challenge testing; and (3) identifying patients and triggering allergens for specific immunotherapy (SIT). Singleplex and multiplex measurement platforms are available for MA diagnostics. The Immuno-Solid phase Allergen Chip (ISAC) is the most comprehensive platform currently available, which involves a biochip technology to measure sIgE antibodies against more than one hundred allergenic molecules in a single assay. As the field of MA diagnostics advances, future work needs to focus on large-scale, population-based studies involving practical applications, elucidation and expansion of additional allergenic molecules, and support for appropriate test interpretation. With the rapidly expanding evidence-base for MA diagnosis, there is a need for allergists to keep abreast of the latest information. The aim of this consensus document is to provide a practical guide for the indications, determination, and interpretation of MA diagnostics for clinicians trained in allergology.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Diagnosis of allergy by an in-vitro test for allergen antibodies.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              How molecular diagnosis can change allergen-specific immunotherapy prescription in a complex pollen area.

              The identification of disease-eliciting allergens is a prerequisite for accurate prescription of allergen-specific immunotherapy (SIT). The aim of this study was to determine whether molecular diagnosis (MD) may change indication and allergen prescription of SIT. A total of 141 patients with allergic rhinoconjunctivitis and/or asthma sensitized to pollen with or without concomitant food allergy were included. Skin prick testing with a panel of aeroallergens and a microarray-based panel of allergens (ISAC(®); Phadia, Sweden) was performed in all patients. Prior to learning the results of molecular diagnosis, three of the authors reached a consensus on the indication of SIT and use of allergens following EAACI recommendations, basing their judgment on clinical history and skin prick test results before and after obtaining the ISAC results. The agreement coefficient (kappa index) was used to analyze the results. Fifty-nine percent of the patients were women with a mean age of 31 ± 13.63. Agreement in SIT indication before and after ISAC(®) results was found in only 62 (46%) patients (kappa = 0.1057 ± 0.0413). Concerning allergens used in the most common prescriptions before and after MD results, we obtained the following results: κ = 0.117 ± 0.0825 for grass; κ = 0.1624 ± 0.0639 for olive; κ = 0.0505 ± 0.0548 for olive and grass; κ = 0.1711 ± 0.0471 for grass and cypress; κ = 0.1897 ± 0.0493 for grass and London plane; κ = 1 ± 0.0842 for olive and cypress, and κ = 0.3586 ± 0.0798 for other combinations. There was very low agreement concerning indication and use of allergens for SIT before and after performing MD. This discrepancy emphasizes the usefulness of MD, at least in areas of complex sensitization to pollen, in determining correct indication of SIT. © 2012 John Wiley & Sons A/S.
                Bookmark

                Author and article information

                Contributors
                enrico.heffler@hunimed.eu
                francesca.puggioni@humanitas.it
                S.Peveri@ausl.pc.it
                M.Montagni@ausl.pc.it
                giorgio_walter.canonica@hunimed.eu
                giovanni.melioli@hunimed.eu
                Journal
                World Allergy Organ J
                World Allergy Organ J
                The World Allergy Organization Journal
                BioMed Central (London )
                1939-4551
                26 April 2018
                26 April 2018
                2018
                : 11
                : 1
                : 7
                Affiliations
                [1 ]ISNI 0000 0004 1756 8807, GRID grid.417728.f, Personalized Medicine, Asthma and Allergy Unit, , Humanitas Clinical and Research Center, ; 20089 Rozzano MI, Italy
                [2 ]GRID grid.452490.e, Department of Biomedical Sciences, , Humanitas University, ; Via Manzoni 113, 20089 Rozzano MI, Italy
                [3 ]Unità Operativa Speciale Dipartimentale di Allergologia, Ospedale G. da Saliceto, Piacenza, Italy
                Article
                186
                10.1186/s40413-018-0186-3
                5918992
                29743964
                51816d5e-4b25-41f4-87d1-a9631532d609
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 1 March 2018
                : 6 April 2018
                Funding
                Funded by: Associazione Ricerca Malattie Immunologiche e Allergiche (ARMIA), Genova, Italy.
                Categories
                Original Research
                Custom metadata
                © The Author(s) 2018

                Immunology
                allergen extract,allergen component,isac,alex,ige assay,laboratory methods
                Immunology
                allergen extract, allergen component, isac, alex, ige assay, laboratory methods

                Comments

                Comment on this article